Immunoblotting analysis
Proteins were extracted by using M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific) with Protease Inhibitor Cocktail (Thermo Fisher Scientific). Nucleus proteins were extracted by using NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific) with Protease Inhibitor Cocktail.Proteins were mixed with an equal volume of Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA, USA) containing 5% 2-mercaptoethanol and then boiled for 5 min prior to separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Precision Plus Protein Kaleidoscope molecular weight markers (Bio-Rad laboratories) were used as standards. The proteins were then electro-transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA) and blocked with 4% Block Ace (KAC Co., Ltd., Kyoto, Japan) in phosphate-buffered saline plus 0.01% (v/v) Triton X-100 (PBST). The membranes were incubated with primary antibody for 1 h and then treated with secondary antibody for 1 h. The following antibodies were used: anti-PGRMC1 monoclonal antibody (mAb) (#13856, 1:1000), antiepidermal growth factor receptor (EGFR) mAb (#4267, 1:1000), anti-phospho-EGFRTyr1068 mAb (#3777, 1:1000), anti-phospho-EGFRTyr992 mAb (#2235, 1:500), anti-phospho-EGFRTyr845 mAb (#6963, 1:500), anti-Akt mAb (#4691, 1:2000), anti-phospho-AktSer473 mAb (#4060, 1:2000), anti-ERK pAb (#9102, 1:2000), anti-phospho-ERKT202/Y204 pAb(#9101, 1:2000), anti-Lamin A/C pAb (#2032, 1:2000)and antirabbit IgG-horseradish peroxidase-conjugated secondary antibody (#7074S, 1:2000) purchased from Cell Signaling Technology (Danvers, MA, USA); and anti-β-actin mAb (A5316,1:50000) and anti-mouse IgG secondary antibody purchased from Sigma-Aldrich (Darmstadt, DE, USA), anti-β-catenin mAb (sc-7963, 1:1000) was purchase from Santa Cruz Biotechnology, Inc., (Dallas, TX, USA). All of them were diluted in 0.4% Block Ace in PBST. The protein bands were detected by using SuperSignalWest Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) and visualized with an ImageQuant LAS 4000 mini biomolecular imager (GE Healthcare Japan, Tokyo, Japan). The resultant images were analyzed by using ImageJ JAVA 1.6.0_24 (64-bit) (National Institutes of Health, Bethesda, MD, USA). where each bar represents a tumor that was found to contain a DNA alteration (13 cases amplification as indicated in red, 1 case deletion as indicated in blue, 7 cases mutation, as indicated in green) in PGRMC1. Figure S8 . Comparison of PGRMC1 expression in osimertinib-sensitive (NCI-H1975) and osimertinibresistant (NCI-H1975/OR) lung adenocarcinoma cancer cells. PGRMC1 expression was monitored by immunoblotting.
MATERIALS AND METHODS (Continue)

